Back HCV Treatment

Merck Submits Grazoprevir/ Elbasvir for FDA Approval, BMS Gets Breakthrough Status for Daclatasvir

Merck has requested U.S. Food and Drug Administration (FDA) approval for its promising grazoprevir/elbasvir coformulation for people with hepatitis C virus genotypes 1, 4, or 6, the company recently announced. In related news, Bristol-Myers Squibb said that the FDA has granted Breakthrough Therapy status for daclatasvir plus sofosbuvir for people with advanced cirrhosis and liver transplant recipients.


Read more: